The Trump administration decided to put the pilot on hold until at least 2027.
The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...
CMS pauses weight-loss BALANCE model for Medicare Part D after insufficient plan sponsor participation, while Medicaid pilot continues.
Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...
The Trump administration will require all 50 states to explain their plans to revalidate some of their Medicaid providers in ...
In a first, the federal government is allowing certain hemp products to be used as treatments for people on Medicare. The new ...
The Trump administration announced that it is indefinitely delaying the implementation of the Medicare Part D portion of the ...
The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...
The Centers for Medicare & Medicaid Services has postponed its BALANCE pilot program for GLP‑1 obesity drug coverage until at least 2027 after insurers balked at costs and risks. In its place, CMS ...
Dr. Mehmet Oz announced an initiative, requiring all 50 states to audit their Medicaid provider networks in a move marking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results